New combo therapy aims to outsmart tough lung cancer mutations
NCT ID NCT04695925
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial compares the standard drug osimertinib alone versus osimertinib combined with two chemotherapy drugs (carboplatin and pemetrexed) as a first treatment for people with advanced non-squamous lung cancer that has both EGFR and TP53 mutations. The study involves 294 participants and aims to see if the combination improves how long the cancer stays under control. It is currently active but no longer recruiting new participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Osimertinib, carboplatin, and pemetrexed
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for people with this specific type of advanced lung cancer, potentially delaying disease progression.
- What could go wrong
- This is a phase 3 trial, but results are not yet available. Adding chemotherapy increases side effects, and the benefit over osimertinib alone is not guaranteed. The study only includes patients with good performance status, so results may not apply to all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR GENE MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Central Hospital of Guangdong Nongken, Zhanjiang Cancer Hospital
Zhanjiang, China
-
Department of Medical Oncology,Cancer Center of Sun Yat-Sen University
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lab-Grown lung tumors could reveal why some drugs work and others fail
- New drug cocktail shows promise for Hard-to-Treat lung cancer
- New combo shrinks lung tumors before surgery in early trial
- New hope for drug-resistant lung cancer: combo therapy enters trial
- Heart drug could boost radiation for brain tumors in lung cancer patients
- New MET inhibitor DO-2 enters human trials for Hard-to-Treat cancers